Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901925 · ClinicalTrials.gov registry record · Early Phase 1
A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
A Early Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT02901925 is a Early Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT02901925, a Early Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining. The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g. proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake and concentration of ABY-029 in resected specimens.
Interventions
- DRUG ABY-029
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2021-06-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02901925
The ClinicalTrials.gov registry entry for NCT02901925 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABY-029 is the first listed.
NCT02901925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02901925 about?
NCT02901925 is a clinical study titled "A Microdose Evaluation Study of ABY-029 in Recurrent Glioma". The primary study objective is to determine if microdoses of ABY-029 lead to detectable signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining. The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI and intraoperative probe rel...
What is the current status of trial NCT02901925?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2017-02-13. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT02901925?
The interventions under investigation include: ABY-029 (DRUG).
Who is sponsoring clinical trial NCT02901925?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.